VEEV

227.08

+2.06%↑

A

105.87

+1.11%↑

WBA

10.98

-0.09%↓

CHE

549.58

+1.15%↑

HQY

85.37

-0.07%↓

VEEV

227.08

+2.06%↑

A

105.87

+1.11%↑

WBA

10.98

-0.09%↓

CHE

549.58

+1.15%↑

HQY

85.37

-0.07%↓

VEEV

227.08

+2.06%↑

A

105.87

+1.11%↑

WBA

10.98

-0.09%↓

CHE

549.58

+1.15%↑

HQY

85.37

-0.07%↓

VEEV

227.08

+2.06%↑

A

105.87

+1.11%↑

WBA

10.98

-0.09%↓

CHE

549.58

+1.15%↑

HQY

85.37

-0.07%↓

VEEV

227.08

+2.06%↑

A

105.87

+1.11%↑

WBA

10.98

-0.09%↓

CHE

549.58

+1.15%↑

HQY

85.37

-0.07%↓

Search

Medtronic PLC

Ouvert

SecteurSoins de santé

83.9 -0.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

83.5

Max

84.58

Chiffres clés

By Trading Economics

Revenu

32M

1.3B

Ventes

-111M

8.3B

P/E

Moyenne du Secteur

24.939

57.333

BPA

1.39

Rendement du dividende

3.39

Marge bénéficiaire

15.798

Employés

95,000

EBITDA

-40M

2.4B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+14.63% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.39%

2.63%

Prochains Résultats

21 mai 2025

Date du Prochain Dividende

11 juil. 2025

Date du Prochain Détachement de Dividende

27 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-16B

105B

Ouverture précédente

84.35

Clôture précédente

83.9

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Medtronic PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 févr. 2025, 12:24 UTC

Résultats

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 nov. 2024, 12:27 UTC

Résultats

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 févr. 2025, 10:30 UTC

Actualités

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 févr. 2025, 11:47 UTC

Résultats

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 févr. 2025, 11:46 UTC

Résultats

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Adj EPS $1.39 >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Net $1.29B >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Diabetes Rev $694M >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q EPS $1.01 >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 févr. 2025, 11:45 UTC

Résultats

Medtronic 3Q Sales $8.29B >MDT

18 févr. 2025, 10:01 UTC

Résultats
Actions en Tendance

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 janv. 2025, 19:15 UTC

Actualités

Medtronic Hires CFO From Renault -- Update

21 janv. 2025, 12:17 UTC

Actualités

Medtronic Hires CFO From Renault

19 nov. 2024, 12:12 UTC

Résultats

Medtronic Narrows FY Guidance as 2Q Tops Views

19 nov. 2024, 11:46 UTC

Résultats

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 nov. 2024, 11:46 UTC

Résultats

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Adj EPS $1.26 >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Diabetes Rev $686M >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Net $1.27B >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 nov. 2024, 11:45 UTC

Résultats

Medtronic 2Q Sales $8.4B >MDT

Comparaison

Variation de prix

Medtronic PLC prévision

Objectif de Prix

By TipRanks

14.63% hausse

Prévisions sur 12 Mois

Moyen 96 USD  14.63%

Haut 109 USD

Bas 85 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

19 ratings

9

Achat

9

Maintien

1

Vente

Score Technique

By Trading Central

82.54 / 84.22Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.